Home › Funds › PRIMECAP MANAGEMENT CO/CA/ › GSK
PRIMECAP MANAGEMENT CO/CA/ position in GSK
GSK PLC · Health Care
PRIMECAP MANAGEMENT CO/CA/ reported holding 25,192,138 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$1.21B, representing 0.75% of its reported portfolio and ranking #35 among its reported holdings. PRIMECAP MANAGEMENT CO/CA/ has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How PRIMECAP MANAGEMENT CO/CA/'s GSK position evolved
PRIMECAP MANAGEMENT CO/CA/ first disclosed a stake in GSK in Q3 2023 at 12,058,770 shares (US$437.1M). The position peaked in Q1 2026 at 25,204,538 shares, worth US$1.39B. Across 13 filings, PRIMECAP MANAGEMENT CO/CA/ increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 25,192,138 shares valued at US$1.21B. Notable position changes include a 70% increase in Q4 2024 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 12.06M | $437.13M | New |
| Q4 2023 | 12.09M | $448.03M | Hold |
| Q1 2024 | 12.74M | $546.09M | Add |
| Q2 2024 | 14.51M | $558.69M | Add |
| Q3 2024 | 14.85M | $607.22M | Add |
| Q4 2024 | 25.26M | $854.35M | Add |
| Q1 2025 | 25.71M | $995.93M | Add |
| Q2 2025 | 27.73M | $1.06B | Add |
| Q3 2025 | 25.77M | $1.11B | Reduce |
| Q4 2025 | 25.13M | $1.23B | Reduce |
| Q1 2026 | 25.20M | $1.39B | Hold |
| Q2 2026 | 25.18M | $1.32B | Hold |
| Q3 2026 | 25.19M | $1.21B | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 19 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), JTC Employer Solutions Trustee Ltd (US$389.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- JTC Employer Solutions Trustee Ltd 8.08M sh · $389.17M · Q3 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.92M sh · $188.73M · Q3 2026
- EQUITY INVESTMENT CORP 3.56M sh · $171.52M · Q3 2026
More on PRIMECAP MANAGEMENT CO/CA/
FAQ
How long has PRIMECAP MANAGEMENT CO/CA/ held GSK?
PRIMECAP MANAGEMENT CO/CA/ has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is PRIMECAP MANAGEMENT CO/CA/'s current position in GSK?
As of Q3 2026, PRIMECAP MANAGEMENT CO/CA/ holds 25.19M shares of GSK (GSK PLC), valued at $1.21B, representing 0.75% of its reported portfolio and ranking #35.
Has PRIMECAP MANAGEMENT CO/CA/ been buying or selling GSK?
In the latest 13F filing (Q3 2026), PRIMECAP MANAGEMENT CO/CA/ held unchanged its position in GSK. The position peaked in Q1 2026 at 25.20M shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, JTC Employer Solutions Trustee Ltd, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.